cancer

Synonymous mutations have long been ignored in cancer studies since they don’t affect the amino acid sequences of proteins. But research increasingly reveals that they can have disease-driving effects.

Although scientists often assume that synonymous mutations don’t cause any biological effects because they don’t alter the amino acid code, recent research shows that they can influence transcription and translation in a variety of ways. 

Susan Thomas discusses how her team engineered a microfluidic device to screen for T cells with improved homing capability to tumor cells. 

Colonizing tumors with engineered bacteria may allow researchers to target sites currently inaccessible to radionuclide therapy.

A battery that charges itself in salty fluids starves tumors of oxygen, helping improve some drugs treat cancer, a study finds.

Researchers find many tumor-specific antigens form when cancer genes and transposable elements link up.

Contact inhibition of locomotion by adhesion receptors prevents cancer cells from eating each other. 

Beyond his achievements in academia, he also cofounded three pharmaceutical companies and filed 15 patents related to cancer therapeutics. 

Cohesin mutations cause dysregulations in alternative splicing, contributing to tumor initiation and progression, a study finds. 

DNA sequencing can identify mutations that predict recurrence of renal cell carcinoma and may help low-risk patients avoid unnecessary treatment, a study finds.

Jumping genes are let loose in cancerous cells, with multiple effects on cell health.

Noncoding RNAs and microproteins, once considered genomic noise, are turning out to be critical to the progression of some types of cancer.

The University of Chicago cell biologist is studying how the nutrients available to cancers influence their growth. 

Transposons may be key players in how tumors develop and spread, but they also keep cancer at bay in some circumstances.